

# Accepted Manuscript

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer

Lorena Ostios-Garcia, MD, Jennifer Faig, MD, Giulia C. Leonardi, MD, Anika E. Adeni, Safiya J. Subegdjo, Christine A. Lydon, Deepa Rangachari, MD, Mark S. Huberman, MD, Kartik Sehgal, MBBS, Meghan Shea, MD, Paul A. VanderLaan, MD, PhD, Matthew P. Cheng, MD, Francisco M. Marty, MD, Sarah P. Hammond, MD, Daniel B. Costa, MD, PhD, Mark M. Awad, MD, PhD

PII: S1556-0864(18)30270-3

DOI: [10.1016/j.jtho.2018.03.031](https://doi.org/10.1016/j.jtho.2018.03.031)

Reference: JTHO 927

To appear in: *Journal of Thoracic Oncology*

Received Date: 19 December 2017

Revised Date: 28 March 2018

Accepted Date: 29 March 2018

Please cite this article as: Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM, Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer, *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.03.031.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer

Lorena Ostios-Garcia, MD<sup>a</sup>; Jennifer Faig, MD<sup>b</sup>; Giulia C. Leonardi, MD<sup>a</sup>; Anika E. Adeni<sup>a</sup>; Safiya J. Subegdjo<sup>a</sup>; Christine A. Lydon<sup>a</sup>; Deepa Rangachari, MD<sup>b</sup>; Mark S. Huberman, MD<sup>b</sup>; Kartik Sehgal, MBBS<sup>b</sup>; Meghan Shea, MD<sup>b</sup>; Paul A. VanderLaan, MD, PhD<sup>c</sup>; Matthew P. Cheng, MD<sup>d</sup>; Francisco M. Marty, MD<sup>d</sup>; Sarah P. Hammond, MD<sup>d</sup>; Daniel B. Costa, MD, PhD<sup>b</sup>; Mark M. Awad, MD, PhD<sup>a</sup>

<sup>a</sup> Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

<sup>b</sup> Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

<sup>c</sup> Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

<sup>d</sup> Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Corresponding authors:

Mark M. Awad, MD, PhD. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Telephone: 617-632-3468. Fax: 617-632-5786. Email: mark\_awad@dfci.harvard.edu; and

Daniel B. Costa, MD, PhD. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. Telephone: 617-667-9236. Fax: 617-975-5665. Email: dbcosta@bidmc.harvard.edu

Running Title: Pembrolizumab and Nivolumab in HIV

Word count: 1596

Figures: 1

Tables: 1

References: 17

Manuscript type: Brief Report

Keywords: lung cancer; HIV; pembrolizumab; nivolumab; PD-1, PD-L1; immunotherapy

Disclosure: Dr. Costa received consultancy fees from AstraZeneca, Takeda and Pfizer. Dr. Hammond received research funding from Merck. Dr. Awad received grants and personal fees from Bristol Myers Squibb and personal fees from Merck and AstraZeneca. The remaining authors declare no conflicts of interest.

Download English Version:

<https://daneshyari.com/en/article/8787584>

Download Persian Version:

<https://daneshyari.com/article/8787584>

[Daneshyari.com](https://daneshyari.com)